e222 Abstracts of the 25 th National Congress of Digestive Diseases / Digestive and Liver Disease 51/S2 (2019) e71–e243 Abstract P.07.2 – Table 1. Factors influencing IBD quality of live and disability, P.07.3 EARLY MEASUREMENT OF SERUM CYTOKINES AS PREDICTOR OF CLINICAL AND ENDOSCOPIC OUTCOME TO VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS L. Bertani *,1 , L. Antonioli 2 , L. Baglietto 2 , G. Tapete 1 , E. Albano 1 , M.G. Mumolo 3 , L. Ceccarelli 3 , S. Maltinti 1 , M. Fornai 2 , S. Marchi 1 , C. Blandizzi 2 , F. Costa 3 1 University of Pisa - Department of New Technologies and Translational Research in Medicine and Surgery, Pisa, Italy; 2 University of Pisa - Department of Clinical and Experimental Medicine, Pisa, Italy; 3 Azienda Ospedaliero-Universitaria Pisana - Department of Surgery and Gastroenterology, Pisa, Italy Background and aim: Ulcerative colitis (UC) is a chronic relapsing disease characterized by inflammatory cell infiltration of the colonic mucosa with release of pro-inflammatory cytokines. Vedolizumab (VDZ) has recently been developed to block integrin α4β7 in order to prevent the transmigration of leukocytes from the endothelium. An analysis of the variation of cytokine pattern during VDZ treat- ment in UC patients has never been performed. The aim of our study was to correlate the cytokine pattern with treatment outcome in terms of mucosal healing (MH) and clinical remission (CR). Material and methods: UC patients treated with VDZ with a con- comitant stable treatment with mesalamine were enrolled. Primary non responders were excluded. Patients were stratified by age, sex, disease extension, previous treatment with anti-TNF,Partial Mayo Score (PMS) and Fecal Calprotectin (FC) levels at week 0. A blood sample was drawn before VDZ infusion at week 0, 6 and 22, and serum cytokines IFN-γ, IL-1β, TNF-α, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-22, IL-23 were evaluated by a fluorescence assay. At the same timepoints, FC and C-reactive protein were assessed. A colonoscopy was performed before starting the treatment and at week 54, where MH, defined as a Mayo Endoscopic Score of 0 or